Cantargia AB

Equities

CANTA

SE0006371126

Biotechnology & Medical Research

Delayed Nasdaq Stockholm 07:59:34 2024-03-28 am EDT 5-day change 1st Jan Change
3.49 SEK +13.53% Intraday chart for Cantargia AB +16.10% -6.63%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Cantargia AB Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia CI
Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis CI
Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer CI
Transcript : Cantargia AB, 2023 Earnings Call, Feb 22, 2024
Cantargia Secures US Approval to Start Patient Recruitment for Pancreatic Cancer Therapy MT
Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIB Trial with Nadunolimab CI
Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy CI
Cantargia Reports Phase I Clinical Progress in the CAN10 Project CI
Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab and Can10 CI
Cantargia Maintains Patent for Cancer Treatment Amid Withdrawal of Third-party Appeal MT
Transcript : Cantargia AB, Q3 2023 Earnings Call, Nov 10, 2023
Cantargia AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Cantargia Seeks SEK59 Million from Share Sale MT
Cantargia Presents New Clinical Data Further Supporting Nadunolimab's Antitumor Activity and A Key Role of Its Target IL1RAP in Pancreatic Cancer CI
Cantargia Reports New Preclinical Data on nadunolimab Potential to Enhance Anti-Tumor Effect of Immunotherapy Presented at CRI-ENCI-AACR CI
Cantargia's Investigational Blood Cancer Drug Wins $1.1 Million External US Grant MT
Cantargia AB Announces New Nadunolimab Clinical Trial in Leukemia Financed by External US Grant CI
Cantargia Gains Orphan Drug Designation in US for Systemic Sclerosis Treatment MT
Cantargia ABExpands Clinical Pipeline and Starts Treatment in Second Program, CAN10, for Autoimmune Diseases CI
Transcript : Cantargia AB, H1 2023 Earnings Call, Aug 22, 2023
Cantargia AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Cantargia AB Receives Regulatory Approval to Start Phase I Clinical Trial for CAN10 CI
Cantargia Publishes ASCO 2023 Poster on Promising Nadunolimab Efficacy in Non-Small Cell Lung Cancer CI
Cantargia AB Promotes David Liberg to Chief Scientific Officer CI
Cantargia AB Announces Executive Changes, Effective June 15, 2023 CI
Chart Cantargia AB
More charts
Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.49 SEK
Average target price
12.67 SEK
Spread / Average Target
+262.94%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Cantargia AB - Nasdaq Stockholm
  4. News Cantargia AB
  5. Sweden's Cantargia to Amass $25 Million in Rights Issue; Shares Up 6%